OncoMatch/Clinical Trials/NCT04178174
Stereotactic Boost and Short-course Radiation Therapy for Oropharynx Cancer
Is NCT04178174 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies non-drug interventions for head and neck cancer.
This is a randomized clinical trial comparing the outcomes of short-course chemoradiation consisting in stereotactic boost to the gross tumor and de-esclalated chemoradiation to the elective neck in human papilloma associated oropharynx cancer vs. the current standard 7-week course chemoradiation.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Biomarker criteria
Required: HPV positive
Positive for HPV by p16 immunohistochemistry (IHC) or HPV in-situ hybridization (ISH)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: irradiation of the head and neck region
Previous irradiation of the head and neck region
Cannot have received: surgery of the HNC region
Exception: except for incisional or excisional biopsies
Previous surgery of the HNC region (except for incisional or excisional biopsies)
Cannot have received: induction chemotherapy
Prior induction chemotherapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04178174 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior irradiation of the head and neck region, surgery of the HNC region, induction chemotherapy disqualifies patients from enrollment.
Does this trial require HPV?
Yes, HPV positive is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages